Clinical Trials on Esophageal Squamous Dysplasia

Total 8683 results

Yang Jianjun, PhD

Not yet recruiting

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma (SG-ESCC)

Esophageal Squamous Cell Carcinoma
RenJi Hospital

Not yet recruiting

Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data

Esophageal Squamous Cell Carcinoma
Ruijin Hospital

Recruiting

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hebei Medical University Fourth Hospital
Xingtai People's Hospital; Handan Central Hospital

Recruiting

Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma (ctDNA)

Esophageal Squamous Cell Carcinoma

China
Shandong Boan Biotechnology Co., Ltd

Recruiting

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Affiliated Cancer Hospital of Shantou University...

Recruiting

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital

Not yet recruiting

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

Esophageal Squamous Cell Carcinoma

China
Fudan University

Not yet recruiting

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

PFS
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC (WATCHER)

Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Keio University

Recruiting

Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel

Esophageal Squamous Cell Carcinoma

Japan
National Cancer Center, Japan

Recruiting

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC (ARMADILLO)

Esophageal Squamous Cell Carcinoma

Japan
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Wuhan University

Recruiting

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital

Recruiting

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) (HCHTOG1903)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Changhai Hospital
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaborators

Enrolling by invitation

Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

Esophageal Squamous Cell Carcinoma

United States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
Sun Yat-sen University

Active, not recruiting

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Completed

The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Completed

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Completed

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma

China
Yuhong Li

Completed

Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
NYU Langone Health

Terminated

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

United States
Peking University

Withdrawn

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

Esophageal Squamous Cell Carcinoma

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen

Completed

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Immunotherapy

China
Fudan University

Unknown

A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC

Esophageal Squamous Cell Carcinoma

China
National Cancer Institute (NCI)

Completed

A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya

Esophageal Squamous Cell Carcinoma

Kenya
Samsung Medical Center

Withdrawn

Genome-wide Association Study

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Peking University

Unknown

Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo) (ECMTPneo)

Esophageal Squamous Cell Carcinoma

China
Fudan University

Completed

Study of S-1 in Combination With Radiotherapy in Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
Fudan University
Fujian Cancer Hospital; Affiliated Hospital of Jiangnan University; First Affiliated... and other collaborators

Completed

A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (nabPCESCC)

Esophageal Squamous Cell Carcinoma

China
Fudan University
Zhejiang Cancer Hospital; The First Affiliated Hospital of Anhui Medical University and other collaborators

Unknown

Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0

Esophageal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Sung Yong Oh

Unknown

Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma (DOSE)

Metastatic Cancer | Esophagus Squamous Cell Carcinoma (SCC)

Korea, Republic of
Hospices Civils de Lyon

Completed

Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial (NESTIS)

Colorectal Neoplasms | Barrett's Esophagus | Intestinal Dysplasia | Esophageal Dysplasia

France
Fudan University

Recruiting

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China

3

Subscribe